Author(s): Dr. Raghavendra Rao N. G
Journal: International Journal of Pharmaceutical Research and Development
ISSN 0974-9446
Volume: 2;
Issue: 9;
Start page: 17;
Date: 2010;
Original page
Keywords: co-processed superdisintegrants | felodipine | fast dissolving tablets | sodium starch glycolate | and crospovidone.
ABSTRACT
In the present study, novel co-processed superdisintegrants were developed by solvent evaporation method using crospovidone and sodium starch glycolate in different ratios (1:1, 1:2 and 1:3) for use in the fast dissolving tablet formulations. The developed excipients were evaluated for angle of repose, Carr’s index and Hausner’s ratio in comparison with physical mixture of superdisintegrants. The angle of repose of the developed excipients was found to be < 300, Compressibility (%) index in the range of 15.22 to 16.88 % and Hausner’s ratio in the range of 1.15-1.27. Felodipine is used in the present study and widely accepted for its excellent antihypertensive and antianginal properties since it is calcium antagonist compound (calcium channel blocker). Fast dissolving tablets of Felodipine were prepared using the above co-processed superdisintegrants and evaluated for pre-compression and post-compression parameters. Effect of co-processed superdisintegrants (such as crospovidone, and sodium starch glycolate) on wetting time, disintegrating time, drug content, in-vitro release, and stability parameters have been studied. The prepared tablets were characterized by FTIR Studies. Based on in-vitro dispersion time (approximately 17 sec), promising formulation CP1 was tested for in-vitro drug release pattern in phosphate buffer pH 6.5 containing 0.1% SLS. Among the designed formulations, the formulation (CP1) containing 4% w/w of co-processed superdisintegrant (1:1 mixture of crospovidone and sodium starch glycolate) emerged as the overall best formulation (t 50% 1.97 min) based on drug release characteristics in phosphate buffer pH 6.5 containing 0.1% SLS. Short-term stability studies on promising formulation indicated that there were no significant changes in drug content and in- vitro dispersion time (p
Journal: International Journal of Pharmaceutical Research and Development
ISSN 0974-9446
Volume: 2;
Issue: 9;
Start page: 17;
Date: 2010;
Original page
Keywords: co-processed superdisintegrants | felodipine | fast dissolving tablets | sodium starch glycolate | and crospovidone.
ABSTRACT
In the present study, novel co-processed superdisintegrants were developed by solvent evaporation method using crospovidone and sodium starch glycolate in different ratios (1:1, 1:2 and 1:3) for use in the fast dissolving tablet formulations. The developed excipients were evaluated for angle of repose, Carr’s index and Hausner’s ratio in comparison with physical mixture of superdisintegrants. The angle of repose of the developed excipients was found to be < 300, Compressibility (%) index in the range of 15.22 to 16.88 % and Hausner’s ratio in the range of 1.15-1.27. Felodipine is used in the present study and widely accepted for its excellent antihypertensive and antianginal properties since it is calcium antagonist compound (calcium channel blocker). Fast dissolving tablets of Felodipine were prepared using the above co-processed superdisintegrants and evaluated for pre-compression and post-compression parameters. Effect of co-processed superdisintegrants (such as crospovidone, and sodium starch glycolate) on wetting time, disintegrating time, drug content, in-vitro release, and stability parameters have been studied. The prepared tablets were characterized by FTIR Studies. Based on in-vitro dispersion time (approximately 17 sec), promising formulation CP1 was tested for in-vitro drug release pattern in phosphate buffer pH 6.5 containing 0.1% SLS. Among the designed formulations, the formulation (CP1) containing 4% w/w of co-processed superdisintegrant (1:1 mixture of crospovidone and sodium starch glycolate) emerged as the overall best formulation (t 50% 1.97 min) based on drug release characteristics in phosphate buffer pH 6.5 containing 0.1% SLS. Short-term stability studies on promising formulation indicated that there were no significant changes in drug content and in- vitro dispersion time (p
